The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
This marks the fourth acquisition by Corona Remedies from multinational corporations
Celecoxib is a nonsteroidal anti-inflammatory drug
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025
Subscribe To Our Newsletter & Stay Updated
